RT @JulianSegan: Denosumab in erosive hand OA. 12-weekly dosing, primary end-point at 24 weeks. @RheumNow #ACR22 #LateB
Tweet Content
Denosumab in erosive hand OA. 12-weekly dosing, primary end-point at 24 weeks.
@RheumNow #ACR22 #LateBreaking
Show on Archive Page
On
Display in Search Results
On
PDQ
Off